Home » Newsletters » BioWorld Science

BioWorld Science

May 21, 2012

View Archived Issues

Data reported on effects of HSC gene therapy for metachromatic leukodystrophy

Sonic hedgehog pathway inhibitors disclosed by U.S. researchers

Teva Pharmaceutical Industries patents novel compounds for MS

Novel histone deacetylase inhibitors prepared by Georgia Tech Research Corp.

Promising results reported for first patients in phase I trial of VRX-007

In vivo studies show new therapeutic potential for CDDO-Me

Daclatasvir shows promise in difficult-to-treat populations

Alisporivir results in hepatitis C virus genotypes 1, 2 and 3 reported

Novel protease inhibitors for HIV patented

Monash University presents new antimicrobial peptides

Merz Pharma designs novel cognition-enhancing drugs

Novel AMPK activators designed by Roche

Anti-marinobufagenin antibody studied in salt-sensitive hypertension

Taisho updates pipeline progress for fiscal 2011

Shionogi reviews pipeline progress of fourth quarter of fiscal 2011

Janssen gains Japanese approval for anti-HIV agent

Agilent set to acquire leading cancer diagnostic company

ArQule and Daiichi Sankyo complete patient recruitment in phase III tivantinib study

Ocera obtains CE Mark for Zysa

Half of target patient population recruited in phase III tasquinimod study

ASLAN obtains global rights to Almirall's DHOdehase inhibitor

Pharmaxis submits NDA for Bronchitol

Helix BioPharma receives clearance for European phase III study in low-grade cervical lesions

MRC Technology and Queen Mary University of London enter multiple GPCR collaborations

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...